#Paris #France #VolitionRx #ESMO 2025 #Cancer Biomarkers

VolitionRx to Present at ELCC 2025

VolitionRx Limited (NYSE AMERICAN: VNRX), a prominent player in the field of epigenetics, is set to make significant waves at the European Society for Medical Oncology's European Lung Cancer Congress 2025 (ELCC 2025) in Paris, France. The congress, scheduled from March 26 to 29, 2025, serves as a global platform for leaders in oncology to share groundbreaking research and innovations.

Presentation Highlights

During the congress, Volition will feature two critical poster presentations showcasing their recent findings on cancer biomarkers, particularly in Non-Small Cell Lung Cancer (NSCLC).

1. Novel Biomarkers Combined with ctDNA

The first poster presentation will delve into Volition's Nu.Q® H3K27Me3 biomarker, particularly its role in enhancing prognostic indicators for overall survival when analyzed alongside circulating tumor DNA (ctDNA). This combination could significantly impact treatment pathways in NSCLC, guiding physicians in making more informed treatment decisions for their patients, ultimately aiming to personalize cancer care.

2. Low-Cost Immunoassay for Early Detection

The second poster will outline the potential of Volition’s Nu.Q® H3.1 immunoassay, designed to be a low-cost solution for the early identification of individuals at heightened risk of developing cancer. The goal here is straightforward yet ambitious: to enable early detection that could lead to improved patient outcomes. Early diagnostics remain essential in the fight against various cancers, as they allow for timely intervention and treatment.

Details of the Presentations

• - Poster Session and Table #282P

- Title: "Early detection of stage I/II NSCLC by immunoassay of crosslinked plasma cell-free nucleosomes"
- Presenter: Jake Micallef, PhD, MBA, Chief Scientific Officer of Volition
- Date and Time: Friday, March 28, 2025, from 1:00 PM to 1:45 PM (CET)

• - Poster Session and Table #395P

- Title: "H3K27Me3-nucleosome is a strong prognostic biomarker in NSCLC: Interim results from the analysis of up to 832 patients at baseline"
- Presenter: Marie Piecyk, PhD, Researcher, Center for Innovation in Cancerology of Lyon (CICLY)
- Date and Time: Friday, March 28, 2025, from 1:00 PM to 1:45 PM (CET)

Both presentations aim to highlight Volition's continued commitment to advancing cancer diagnostics through innovative research and development.

About VolitionRx

Founded to harness the potential of epigenetics, VolitionRx is at the forefront of developing simple, reliable, and cost-effective blood tests for a range of diseases, including various cancers. Their mission focuses on early detection and monitoring, striving not only to extend patient life through timely diagnosis but also to enhance the quality of life.

With its research headquartered in Belgium, and locations in the U.S. and the UK, VolitionRx's multidimensional approach to cancer diagnostics leverages innovative techniques to improve patient outcomes worldwide. The company remains dedicated to transforming cancer treatment through technological advancement and grounded research.

By attending the ELCC 2025, VolitionRx continues to push the boundaries of cancer research, aiming to ensure that patients receive the best possible care through early diagnosis and personalized treatment plans. Keep an eye on their presentations for this critical area of research that may reshape expected cancer outcomes for countless individuals.